Urinary Tract Infection Treatment

Introduction to Treatment

• Uncomplicated urinary tract infections can be treated with various antibiotics, with nitrofurantoin being a recommended first-line agent for women, according to the European Urology and Clinical Infectious Diseases guidelines 1, 2

First-Line Treatment

• Nitrofurantoin is recommended as a first-line agent for uncomplicated cystitis in women, with a dosing of 100 mg twice daily for 5 days, due to its low resistance rates compared to other antibiotics 1, 2

Contraindications and Interactions

• Renal impairment is a contraindication for nitrofurantoin, but estradiol allergy is not, with no documented cross-reactivity between nitrofurantoin and estradiol 1, 2
• Nitrofurantoin interacts with spironolactone, but not with estradiol 3

Treatment Options

• Available treatment options for uncomplicated urinary tract infections include:

Monitoring and Adverse Events

• No special monitoring is needed for short-course therapy in patients with estradiol allergy, but prolonged therapy (>3 months) requires monitoring for pulmonary symptoms, liver function abnormalities, and neurological symptoms 1
• Exogenous estrogens, including vaginal estrogen, are contraindicated in women with a history of breast cancer or other estrogen-sensitive cancers, as recommended by the National Comprehensive Cancer Network and the American Academy of Dermatology 4, 3
• Vaginal estrogen may be considered for women with non-hormone-sensitive cancers who develop vasomotor symptoms from cancer treatment, with a favorable safety profile, and should be used at the lowest effective dose for the shortest duration needed 4, 5
• Regular monitoring with evaluation of treatment response after 4-6 weeks is recommended, and abnormal vaginal bleeding requires prompt evaluation 6
• Non-hormonal options such as vaginal moisturizers, topical vitamin D or E, water or silicone-based lubricants, pelvic floor physical therapy, and lidocaine can be considered for women with contraindications to estrogen therapy, as recommended by the National Comprehensive Cancer Network 4, 7

Special Considerations

• For patients on aromatase inhibitors, estriol-containing preparations are preferable to estradiol, but caution is still warranted as vaginal estradiol may increase circulating estradiol levels within 2 weeks of use 7
• The following table summarizes the treatment options and considerations: